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Abstract
Background: Myopalladin (MYPN) is a component of the sarcomere that tethers nebulin in skeletal muscle and
nebulette in cardiac muscle to alpha-actinin at the Z lines. Autosomal dominant MYPN mutations cause hypertrophic,
dilated, or restrictive cardiomyopathy. Autosomal recessive MYPN mutations have been reported in only six families
showing a mildly progressive nemaline or cap myopathy with cardiomyopathy in some patients.
Case presentation: A consanguineous family with congenital to adult-onset muscle weakness and hanging big toe
was reported. Muscle biopsy showed minimal changes with internal nuclei, type 1 fiber predominance, and ultrastructural
defects of Z line. Muscle CT imaging showed marked hypodensity of the sartorius bilaterally and MRI scattered abnormal
high-intensity areas in the internal tongue muscle and in the posterior cervical muscles. Cardiac involvement was
demonstrated by magnetic resonance imaging and late gadolinium enhancement. Whole exome sequencing
analysis identified a homozygous loss of function single nucleotide deletion in the exon 11 of the MYPN gene in
two siblings. Full-length MYPN protein was undetectable on immunoblotting, and on immunofluorescence, its
localization at the Z line was missed.
Conclusions: This report extends the phenotypic spectrum of recessive MYPN-related myopathies showing: (1)
the two patients had hanging big toe and the oldest one developed spine and hand contractures, none of these
signs observed in the previously reported patients, (2) specific ultrastructural changes consisting in Z line fragmentation,
but (3) no nemaline or caps on muscle pathology.
Keywords: Myopalladin (MYPN), Z line, Hanging big toe, Cardiomyopathy, Contractures, Congenital muscular dystrophy
Background
Four patients in four families were recently described with
a mild childhood-to adult onset slowly progressive nema-
line myopathy with intranuclear rods and cardiac problems
caused by biallelic mutations in myopalladin (MYPN) [1].
Homozygous truncating mutations in MYPN were sub-
sequently reported in other two families, in which three
patients presented with a slowly progressive cap myopathy
characterized by facial, axial, hip-girdle, and distal weak-
ness, but not cardiac alterations [2, 3].
MYPN is a component of the sarcomere that tethers
nebulin in skeletal muscle and nebulette in cardiac
muscle to alpha-actinin at the Z lines [4]. Heterozygous
variants in MYPN have been associated with different
cardiac phenotypes: dilated, hypertrophic, or restrictive
cardiomyopathy [5–7], even if some reports should be
reanalyzed [8].
The “hanging big toe” sign, that is highlighted in an
attempt to extend the toes and is due to a selective
weakness of the extensor hallucis longus, has been
reported in Laing early-onset distal myopathy [9] due to
mutations in the slow skeletal muscle fiber myosin heavy
chain gene (MYH7) [10].
Here, we described a congenital myopathy with hanging
big toe and cardiac problems due to a novel homozygous
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MYPN mutation resulting in myopalladin deficiency and
in a peculiar ultrastructural disruption of the regular
square pattern of the Z line, but no nemaline or caps on
muscle pathology.
Case presentation
Clinical and pathological features
The proband (II.2) was the second child of healthy con-
sanguineous parents. He was born at 36 weeks of ges-
tation and needed supplemental oxygen to help breathing.
At age 4months, poor head control was noted. Because of
delayed motor milestones he underwent a biopsy of the
vastus lateralis muscle at age 9months. He started walking
after age 18months. He was never able to run or hop.
Toe-walking was noted at age 10 years. He was examined
by us the first time at 14, and then at 23, 26, and 35 years
of age.
On physical examination, at age 14, he was below the
fifth centile for height and weight. He was able to climb
stairs without aid but not to walk on heels. He showed
amyotrophy of sternal portion of the pectoralis muscle
and hypotrophy of brachioradialis and of the dorsalis
muscles. He was unable to bury the eyelashes. There
was a mild weakness (MRC 4/5) of the shoulder and hip
girdles and proximal limb muscles. Muscle strength was
more decreased in the axial and distal muscles with neck
flexors (2), abdominals (3), finger flexors and extensors,
and foot and toe extensors (4). There was pes cavus
deformity and severe extensor hallucis longus weakness
(0) resulting in hanging big toe. Serum creatine kinase
was normal and EMG of tibialis and quadriceps was
myopathic. A muscle biopsy was performed on the left
quadriceps muscle (see below).
During the twenties, he experienced more difficulty
with stairs. At age 26, in addition to the hanging big toe
sign (Fig. 1a), he showed mild ptosis, mild weakness of
orbicularis oris muscle, nasal voice, more evident atrophy
of the sternal portion of the pectoralis major muscle, some
limitation in flexion of the cervical and lumbar spine,
and limited extension of the wrist and fingers. Knee
extensors were 138 N on the right and 181 N on the
left (normal > 250 N).
When examined at age 35, he had a waddling gait and
needed a banister to climb stairs. Some deterioration in
muscle strength was noted in the axial and distal mus-
cles: neck flexors (1), abdominals (2), finger flexors (3),
hand muscles (3+), and toe extensors (3+). Knee exten-
sors measured 103 N on the right and 126 N on the left.
Muscle CT at age 14 (Fig. 1b) showed at mid-thigh
marked hypodensity of the sartorius bilaterally and of
less extent of the upper part of the gracilis. MRI at age
35 (Fig. 1c) showed scattered abnormal high-intensity
areas in the internal tongue muscle and in the posterior
cervical muscles.
The patient underwent periodic cardiac evaluation. No
family history of cardiac disease or of sudden death was
present. At 26, he was asymptomatic, the ECG was
normal apart from mild voltage increase, and the echo-
cardiogram showed biventricular normal volumes and
ejection fraction (left ventricular EF 55%). At the age of
Fig. 1 Clinical image, muscle CT, tongue MRI, and cardiac MR. Clinical image (a) showing the “hanging big toe sign”. Muscle CT of the mid-thigh
(b) enlightens a selective pattern of involvement with the sartorius (s) and gracilis (g) muscles respectively severely and moderately affected, and
the other muscles still well preserved. T1 weighted tongue MRI (c) shows scattered abnormal high-intensities areas (asterisks) in the
internal tongue structure and the diffuse involvement of the posterior extensor muscles of the cervical spine. Cardiac magnetic resonance
long-axis image (d) shows linear subepicardial late enhancement in the mid and apical segments of the inferolateral wall of the left
ventricle (white arrows)
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36, he repeated complete cardiac evaluation. He contin-
ued to deny any cardiac symptoms. The ECG showed
first-degree atrioventricular block (PR 208ms) and left
anterior hemiblock (QRS 122ms) with high ventricular
voltages. Twenty-four-hour Holter monitoring revealed
a marked sinus arrhythmia with 42 to 120 beats/min
and rare ventricular ectopic beats. The echocardiogram
revealed worsening of left ventricular (LV) EF, then the
patient underwent cardiac magnetic resonance (CMR).
The CMR showed normal LV size (LV indexed
end-diastolic volume of 63 mL/m2), a LVEF of 44%, and
a normal LV mass index of 54 g/m2. On late gadolinium
enhancement (LGE) imaging (Fig. 1d), there was a sube-
picardial enhancement of the inferior and inferoseptal
mid-ventricular segments attributable to interstitial
changes (fibrosis). His forced vital capacity was 2530mL
(55% of predicted) at the age of 23 and 2220 mL (51%)
at age 35.
On physical examination, the parents and the older
brother, aged 39, had normal muscle strength in particu-
lar of the big toe extension, and no muscular atrophy or
contractures. The younger sister (II.3), aged 26, reported
having little strength in her hand but had never sought
medical attention for this. On examination, she had
muscle weakness in neck flexors (4), finger flexors and
extensors (4), finger abductors (4), shoulder abductors
(4), foot extensors (4), and big toe extension (4-). There
was also mild weakness of eye closure and atrophy of
the pectoralis major muscle on the right. Serum creatine
kinase was normal and forced vital capacity was 2070
mL (93%). The ECG and color Doppler echocardio-
graphy were normal.
Molecular and protein analysis
We performed whole-exome sequencing on both af-
fected sibling and consanguineous healthy parents.
This approach showed a homozygous loss of function
single nucleotide deletion: chr10:69934153, c.2304delC,
and p.Ser769LeufsTer92 in the exon 11 of MYPN in the
affected members (II.2, II.3, Fig. 2a). By Sanger sequen-
cing, we confirmed that they have homozygous frameshift
variant while the healthy parents (I.1, I.II., Fig. 2a) were
heterozygous. Unaffected brother did not present the
variant (II.1, Fig. 2a).
This variant was reported in ExAC (http://exac.broad-
institute.org/variant/10-69934149-AC-A) in heterozygos-
ity only 2/121,380 alleles (frequency 0,000016), while in
GnomAD (https://gnomad.broadinstitute.org/variant/10-
69934149-AC-A) in heterozygosity only, with an allele
frequency of 0.000007965, but never in homozygosity,
like all the other loss-of-function variants in this gene.
The resulting protein product is predicted to be short-
ened and degraded. Both heterozygous parents and their
first son were healthy, confirming the recessive nature of
the variant.
To understand whether the homozygous single nu-
cleotide deletion could affect the mRNA expression, we
performed RNA analysis by RT-PCR. RNA was extracted
from patient and healthy control muscle biopsies. The
mRNA transcript level showed no difference compared
to healthy control (Fig. 2b). Primers were designed to
amplify exon–exon junction region (from exon 10 to
exon 12). The Sanger sequence of patient cDNA con-
firmed the homozygous mutation: c.2304delC at RNA
level (Fig. 2c).
The morphological analysis of the quadriceps
muscle biopsy of the index patient taken at age 14
showed a moderate variability of fiber size, increased
number of internal nuclei, and a moderate increase of
the perimysium. Succinic dehydrogenase, cytochrome
c oxidase, and Gomori modified trichrome staining
did not reveal significant changes, while adenosine tri-
phosphatase at pH 10.4 (not shown) showed a clear
predominance of type I fibers, as also confirmed by
immunohistochemistry with anti-myosin heavy chain
7 antibody (Fig. 3a).
To assess the impact of the p.Ser769LeufsTer92 va-
riant on myopalladin protein expression, we performed
western blot analysis of control and patient muscle
lysates. Myopalladin was detected with a rabbit polyclonal
anti-myopalladin antibody (HPA061494 SIGMA, raised
against aa 536-614 of MYPN). Muscle controls showed
the full-length 145 kD myopalladin and a lower additional
band which could correspond to the 114 kD MYPN
isoform 2 (https://www.uniprot.org/uniprot/Q86TC9). In
the patient muscle extract, both the 145 kD full-length
and the 114 kD isoform were absent, even when a higher
amount of protein was loaded. Two additional bands at 25
and 30 kD were present both in control and patient
muscle lysates, possibly due to unspecific signal or
uncharacterized shorter isoforms (Fig. 3b). The immuno-
fluorescence analysis performed with the anti-MYPN anti-
body showed a moderate reduction of signal in patient
muscle sections and some scattered negative fibers. Rare
fibers (0.5% out of 600 fibers) displayed subsarcolemmal
accumulation of MYPN staining (Fig. 3c). Similar results
(not shown) were obtained with a previously characterized
[4] polyclonal anti-MYPN antibody (a friendly gift from
Dr. Labeit, Mannheim, Germany).
Double labeling with anti-MYPN and α-actinin anti-
bodies showed that unlike normal protein, the patient
MYPN residue did not co-localize with α-actinin and
distributed among the myofibrils (Fig. 3d).
Transmission electron microscope analysis revealed
striking alterations of the Z line in the patient biopsy.
Transversal and longitudinal sections of control muscle
Z line showed a regular square pattern, due to the
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presence in this area of cross-linking components, in-
cluding myopalladin [11, 12]. Myopalladin mutation dis-
rupts the regular square pattern of the Z line, which
appeared fragmented. In addition, focal subsarcolemmal
areas with accumulation of disorganized myofilaments
and tiny nemaline-like structures were detected in rare
patient’s myofibers (Fig. 3e).
Discussion
Here, we described a congenital myopathy with hanging
big toe and cardiac involvement due to a novel homozy-
gous MYPN mutation resulting in myopalladin deficiency
and in a peculiar ultrastructural stretching of Z line. This
was made possible thanks to the unbiased genetic
approach based on the analysis of the entire family by
next-generation sequencing [13].
The index patient was floppy at birth, had delayed
motor milestones, and presented in his early teens with a
prevalent axial and distal four limbs weakness with hang-
ing big toes and mild facial weakness. In the following
20 years, he had some progression of proximal and distal
weakness, while remaining completely ambulant, and he
showed initial signs of cardiomyopathy. His sister in the
third decade of life presented muscle weakness with
similar distribution but much milder.
Recessive MYPN mutations have been reported in
seven patients from six families [1, 3] showing some
common features in the clinical phenotype but also va-
riable age of onset, muscle weakness distribution, disease
severity, cardiorespiratory involvement, and muscle
pathology. Our family further broadens the clinical
spectrum of MYPN-related myopathies. Traditionally,
diagnostic workup of cases occurred following clinical
evaluation and muscle biopsy. This is changing, as
genetic testing is increasingly the primary diagnostic ap-
proach, resulting in ever-expanding genotype-phenotype
associations [14].
Our two affected sibs had a markedly different age of
onset and severity of the disease. The presence of intra-
familial variability in patients sharing the same mutation
Fig. 2 Segregation analysis and results of MYPN cDNA analysis. a MYPN DNA Sanger sequencing. Patients II.2 and II.3 were homozygous for
p.Ser769LeufsTer92 in exon 11. Unaffected consanguineous parents were heterozygous (I.1, I.2), and unaffected brother did not show the variant
(II.1). b RT-PCR on the MYPN coding sequencing using primers pairs: MYPN_c.1879F TCTTTCCAGGAGAGGTTCAACG and MYPN_c.2666R TTCC
CCAAGTCTCGAATCACTG. The RT-PCR generated a fragment from exon 10 to exon 12. The patient mRNA transcript level was similar to the
healthy control. c Sanger sequence of amplified region on the patient and control
Merlini et al. Skeletal Muscle            (2019) 9:14 Page 4 of 7
Fig. 3 Histopathology of the patient muscle biopsy and MYPN analysis. A Minimal changes of the muscle architecture with hematoxylin-eosin
(HE) and Gomori modified trichrome staining (TRG). A clear predominance of slow type muscle fibers is evident with anti-myosin heavy chain 7
antibody (MYH7) labeling. Scale bar, 100 μm. B Western blot analysis of muscle lysates from two healthy controls (ctr 1 and ctr 2) and from the
patient loaded at the same protein concentration of controls (60 μg) and at higher concentration (100 μg). In control lysates, MYPN antibody
identifies a clear band at the predicted molecular weight of the full-length MYPN isoform (red arrow), and a lower additional band which could
correspond to the 114 kD MYPN isoform 2 (blue arrow). Additional bands (black arrows) corresponding to uncharacterized isoforms or nonspecific
signal are also present. In patient, the full-length MYPN is absent, as well as the band around 100 kD, while the bands at 25 and 30 kD are similar
to the controls. GAPDH was used as loading control. C Immunofluorescence analysis of MYPN. Note the diffuse reduction of protein, a negative
fiber (asterisk), and protein accumulation in rare subsarcolemmal areas (insert) in patient muscle fibers if compared with the even distribution of
control muscle. Blue staining, DAPI. Scale bar, 100 μm. D Double labeling of MYPN (green) and α-actinin (α-ACTN, red) in control (ctr, upper panels)
and patient (lower panels) muscle sections. In patient muscle, the residual MYPN does not colocalize at Z line with α-actinin and appears diffuse
among myofibrils. Scale bar, 2 μm. E Transmission electron microscope analysis of control (a, b) and patient (c–f). Note the interruption of the square
arrangement (arrows in c) and the focal loss of actin filaments at the Z line (arrows in d) in patient muscle fibers when compared with the ordered
organization in control sections (a, b). Aspects of myofilament disorganization (asterisk in e) and tiny nemaline-like structures (arrowheads in f) in
subsarcolemmal areas of rare patient fibers. Scale bar, 200 nm
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is not uncommon, suggesting that the clinical variability
may be related to the genetic background or modifier
gene(s) of each patient [15]. In our patients, foot exten-
sion was weak with extensor hallucis longus weaker than
tibialis anterior and extensor digitorum longus, resulting
in hanging big toe sign particularly evident in the index
case. This sign has been considered the hallmark of
Laing distal myopathy, an early-onset autosomal domi-
nant disease, due to mutations of slow β-myosin heavy
chain (MYH7) gene [16]. Contractures were not ob-
served in the previously reported cases although they
also had axial [1, 3] and finger flexion weakness [3] while
our patient showed limited flexion of the neck and spine
and limited extension of the wrist and fingers, a type of
contractures that are instead common in Bethlem myop-
athy [17, 18] in which the same muscles are involved.
Muscle imaging in the patients with recessive muta-
tions in MYPN showed early involvement of the sartor-
ius and gracilis [1, 3], in addition to atrophy and fatty
infiltration of the axial, and hip girdle muscles [1, 3], and
a peculliar fatty infiltration of the tongue in one patient
[3]. Our patient with a congenital onset of weakness
showed at age 14 a similar involvement of the axial and
thigh muscles, but also of the pectoralis and psoas
muscles, like the one we noticed in the figures of the
patients described above [1]. At age 35, he also had fatty
infiltrations of the tongue.
Muscle histology of patients with MYPN mutations
has shown type 1 fiber predominance and the presence
of subsarcolemmal caps [3] or nemaline bodies and
intranuclear rods in muscle fibers [1, 3] associated with
a dramatic reduction of myopalladin protein expression.
The muscle biopsy pathology in our patient, at variance
with the other reported MYPN cases, showed only min-
imal changes, with internal nuclei, and type 1 fiber pre-
dominance, but no caps or nemaline bodies, as revealed
by conventional histoenzymatic reactions. By muscle
RNA analysis, we found that mutated mRNA escaped
from nonsense-mediated decay. However, the western
blot analysis revealed that, like in the other cases, the
myopalladin full-length isoform was absent, suggesting
that a truncated protein could be quickly degraded, or a
protein poorly translated from the mutant mRNA.
Additionally, in our patient, the localization of myo-
palladin at the Z line was missed, as shown by immuno-
fluorescence analysis with anti-α actinin, pointing to the
destabilization of Z line integrity. Interestingly, the ultra-
structural analysis showed the presence of Z line alter-
ations in several fibers, consisting in Z line fragmentation
and disruption of the regular square pattern. To our
knowledge, these peculiar ultrastructural alterations have
never been reported in patients with MYPN mutations or
other forms of congenital muscular dystrophies. Z line
streaming and thickening or nemaline rods have been
described in the muscle of patients with MYPN mutations
[1, 3], and both alterations may be found in patients with
recessive slowly progressive congenital myopathy [3]. We
suggest that the Z line fragmentation detected in our
patient represents an early manifestation of Z line
destabilization due to loss of myopalladin and that
the ultrastructural analysis may be informative in
cases without specific typical histopathological features.
Conclusions
Our findings reveal that this family had a congenital to
adult-onset mildly progressive myopathy with hanging big
toe, spine and hand contractures, and cardiomyopathy
and no features of nemaline or cap myopathy, but with
specific ultrastructural changes consisting in disruption of
the regular square pattern of the Z line, extending the
clinical heterogeneity of recessive MYPN mutations.
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